secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2026-08-13T20:32:38+00:00
Accession:  0001477932-26-004991
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q2 2026: H1 revenue up 112% to $1.4M, operating loss down 34%
------------------------------------------------------------------------

- H1 2026 revenue $1.4M, up 112% YoY; Q2 revenue ~$0.4M, flat YoY.
- Q2 operating loss $4.2M, down 34% YoY; operating expenses down 32%.
- Net cash used in ops $5.2M in Q2, down 18% YoY; raised $5.3M from equity sales.
- In talks with 12+ diagnostic/liquid biopsy firms for licensing; Sysmex collaboration announced.
- Nu.Q Vet feline assay manuscript submitted; publication could unlock $5M milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793226004991/0001477932-26-004991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793226004991/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-004991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer